Please assess the completion status of the following clinical trial:

Trial Title: EMD 640 744 in Montanide ISA 51 VG Administered in Subjects With Advanced Solid Tumors

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female subjects ≥18 years of age~* Signed written informed consent~* Histologically or cytologically documented metastatic or locally advanced survivin-expressing solid tumor for which no established therapy exists~* Disease must be measurable by RECIST criteria or evaluable by clinical, radiographic, or laboratory criteria established for the given tumor entity~* Expressing at least one of the following HLA alleles:HLA-A1,-A2,-A3,-A24, and -B7 assessed by HLAgenotyping~* ECOG performance status of ≤1, estimated life expectancy of at least 3 months~* Adequate hematological function defined by WBC ≥3 x 10x9/L, lymphocyte count ≥0.5 x 10x9/L, hemoglobin ≥10 g/dL, platelet count ≥100 x 10x9/L~* Adequate blood coagulation parameters defined as aPTT and INR ≤ 1.5 x ULN~* Adequate renal function defined by a serum creatinine ≤2 x ULN~* Adequate hepatic function defined by total bilirubin ≤2 x ULN and AST and ALT levels ≤2.5 x ULN (in subjects with liver metastases ≤5 x ULN)~* Effective contraception for female and male subjects if the risk of conception exists~Exclusion Criteria:~* Treatment in another clinical study within the past 30 days prior to the first administration of study treatment~* Previous treatment with an investigational anticancer vaccine~* Requirement of concurrent treatment with a nonpermitted drug~* Active significant autoimmune disease (with the exception of vitiligo)~* Receipt of allogeneic stem cell transplantation~* Significant acute or chronic infections (e.g. viral hepatitis, HIV)~* Primary brain tumors and brain metastases (with the exception of brain metastases that are stable after irradiation or surgically resected brain metastases if subjects have been asymptomatic for ≥6 months)~* Rapidly progressive disease (e.g. tumor lysis syndrome)~* Radiotherapy, chemotherapy, surgery (excluding prior diagnostic biopsy), immunotherapy or any investigational drug within 30 days before the start of study treatment~* Pregnancy or lactation~* Active drug or alcohol abuse~* Known hypersensitivity to the study treatment or any of its components~* Any significant disease that, in the Investigator's opinion, should exclude the subject from the study; for questions about this criterion, the Investigator should contact the sponsor.~* Persisting toxicity related to prior therapy ≥grade 2 National Cancer Institute-Common Terminology Criteria For Adverse Events version 3.0~* Legal incapacity or limited legal capacity

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1 (Type: EXPERIMENTAL): EMD 640744 30μg and Montanide® ISA 51 VG
- Group 2 (Type: EXPERIMENTAL): EMD 640744 100μg and Montanide® ISA 51 VG
- Group 3 (Type: EXPERIMENTAL): EMD 640744 300μg and Montanide® ISA 51 VG

Based on this trial design, predict the completion outcome and termination type (if applicable).